Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Double-Blind, Parallel-Group Study Evaluating the Safety, Tolerability, and Efficacy of OV101 in Fragile X Syndrome

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Acronyms ROCKET
  • Sponsors Ovid Therapeutics

    • Most Recent Events

    • 22 Apr 2021 Results from STARS and ROCKET; assessing impact and importance of optimizing of gaboxadol dosing regimens, presented at the 73rd Annual Meeting of the American Academy of Neurology
    • 12 Oct 2020 According to an Ovid Therapeutics media release, data will be presented at the Child Neurology Society/International Child Neurology Association (CNS/ICNA) 2020 Virtual Congress.
    • 10 Aug 2020 According to an Ovid Therapeutics media release, the company plans to meet with regulatory authorities to discuss the future development path and registration pathway.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top